A low‑cost diuretic known as spironolactone may aid stroke survivors whose blood pressure remains high despite standard treatment, according to results presented at the American Heart Association’s Scientific Sessions in Chicago on November 6‑9, 2026. The REDUCE trial, a randomized study, examined whether adding spironolactone to routine post‑stroke care could improve home‑measured blood pressure over a six‑month period.
Study Design and Findings
The trial enrolled 160 participants, assigning half to receive spironolactone in addition to their existing regimen and the other half to continue with usual post‑stroke care. Researchers collected blood‑pressure readings taken at participants’ homes at three‑month and six‑month intervals. At the three‑month mark, the average systolic pressure among those taking spironolactone was roughly eight points lower than in the control group—about 126 mm Hg versus 133 mm Hg. Moreover, 52 % of the spironolactone group achieved the guideline target of less than 130/80 mm Hg, compared with just 30 % of patients receiving standard care.
“Lowering blood pressure is the most important step in preventing another stroke, yet many survivors struggle to reach recommended blood pressure targets after a stroke,” said Dr. Jordana Cohen, co‑lead author and associate professor of medicine and epidemiology at the University of Pennsylvania. She added that the addition of spironolactone produced “a meaningful drop in blood pressure that may lower the risk of future strokes and heart attacks.”
Safety Considerations
Spironolactone acts as a potassium‑sparing diuretic, helping the body eliminate excess salt and water while retaining potassium. The drug’s prescribing information notes that potassium levels must be monitored, as elevated potassium can occur without symptoms and poses a particular risk for individuals with kidney disease or those taking certain other medications or supplements. Dr. Alfred Joshua, a board‑certified emergency physician who was not involved in the study, cautioned that high potassium is a primary safety concern and that the medication can also cause dizziness by lowering blood pressure too much. He advised patients with persistently high readings after a stroke to discuss the medication with their clinicians.
Limitations and Next Steps
The REDUCE trial concluded earlier than planned, enrolling 160 participants instead of the intended 200, and about 15 % of participants lacked blood‑pressure data at the three‑month checkpoint. Additionally, participants receiving spironolactone were on slightly more antihypertensive drugs overall than those in the control arm, which could have contributed to the observed differences. The study was not designed to assess whether spironolactone reduces the incidence of subsequent strokes or heart attacks; larger, longer‑term trials will be needed to answer that question.
While the findings demonstrate a promising blood‑pressure benefit, experts emphasize that controlling hypertension remains the cornerstone of secondary stroke prevention, and any medication changes should be guided by a healthcare professional.
Helene Elliott is the Lead Science & Space Reporter at News Raise. She reports on aerospace missions, astrophysics discoveries, quantum research, and environmental technology.




